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ABSTRACT
Highly active antiretroviral therapy (HAART) has changed the morbidity pattern affecting HIV-infect-
ed individuals to include non-AIDS-defining cancers. We describe the breast cancer cases occurring 
in a cohort of 860 HIV-infected women followed in Rio de Janeiro, Brazil, and estimate the incidence 
rate of breast cancer for this population. Nine cases were identified; median age at diagnosis was 46 
years. Median survival after breast cancer diagnosis was 12 months. Breast cancer diagnosis was made 
within 2 to 15 years of HIV-infection diagnosis. At breast cancer diagnosis, CD4 counts ranged from 
135 to 782 cells/mm3; six women were receiving HAART. Histological analysis indicated infiltrating 
ductal carcinoma in all cases. The incidence rate of breast cancer was 133 cases per 100,000 persons-
year. Patients from our case series were late diagnosed with breast cancer and thus suffered from worse 
prognosis. Strategies targeting earlier diagnosis and prompt initiation of treatment are needed.
Keywords: HIV; breast neoplasms; case reports; incidence.
INTRODUCTION
Worldwide, since the introduction of highly 
active antiretroviral therapy (HAART), the life 
expectancy of HIV-infected individuals has 
increased while the incidence of both oppor-
tunistic infections and AIDS-defining cancers 
has dramatically decreased.1-3 A new morbidity 
pattern has emerged which includes complica-
tions associated with treatment toxicity, coin-
fections (in particular hepatitis B and C), car-
diovascular diseases, bacterial infections and 
non-AIDS-defining cancers.4,5
Breast cancer, a non-AIDS-defining ma-
lignancy, has not been shown to occur with 
greater incidence among HIV-infected wom-
en when compared to the general female 
population.3,6-8 Although it has been suggest-
ed that breast cancer in the setting of HIV 
disease has a more aggressive clinical course 
and poorer outcome,9,10 these findings are 
controversial.11,12
Treatment decisions in patients with HIV 
and breast cancer are complicated by the 
risk of immunological and hematological 
toxicities and by the complex drug interac-
tions between chemotherapeutic agents and 
HAART. There is also the possibility for the 
progression of HIV disease in the setting of 
cytotoxic therapy. Breast cancer case series 
have been reported in the literature,10-14 but 
more information is needed in order to bet-
ter understand the interactions between the 
two diseases.
In Brazil, breast cancer is currently the 
most common malignancy among women, 
with 49,400 new cases expected to occur 
in 2009.15 Most cases are late diagnosed 
thus limiting the treatment options.16,17 To 
date, there are no reports of breast cancer 
case series or breast cancer incidence for 
HIV-infected women from Brazil or Latin 
America as a whole. In this study, we report 
on the breast cancer cases occurring in a 
cohort of HIV-infected women followed at 
Rio de Janeiro, Brazil. We give information 
on the socio-demographic, clinical, patho-
logical and survival characteristics. Also, we 
estimate the incidence rate of breast cancer 
within the cohort.
MATERIALS AND METHODS
To study the natural history of HIV infec-
tion in women, a prospective open cohort 
was established at the Instituto de Pesquisa 
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Clínica Evandro Chagas (IPEC), Fundação Oswaldo Cruz, 
Rio de Janeiro, Brazil. From the cohort’s onset in May 
1996 up until September 2009, 860 women have enrolled 
the cohort after signing an informed consent that in-
quired on willingness to participate and attend all medical 
appointments. Cohort procedures and baseline infor-
mation on the prevalence of sexually transmitted infec-
tions, including human papillomavirus virus infection, 
and of squamous intra-epithelial cervical lesions and 
its determinants have been published.18-20 Briefly, bi-
annual medical appointments evaluate gynecologi-
cal signs and symptoms, pelvic examination with speci-
men collection, breast examination, sexual and behavioral 
practices, and reproductive counseling. For all cases, di-
agnosis was confirmed through histological analysis con-
ducted by pathologists at either Instituto Fernandes Fi-
gueira, a women’s and children’s reference center of 
Fundação Oswaldo Cruz or the National Institute 
of Cancer. The TNM system for staging malignant tumors 
was used. It gives information on the extent of the prima-
ry tumor (T), of regional lymph node (N) metastasis, and 
of distant metastasis (M). Treatment was individualized, 
according to disease staging, tumor hormonal receptor 
susceptibility, patient’s clinical condition and comorbidi-
ties. CD4+ T-cell count (Becton Dickinson FACScan) were 
obtained from the participant’s medical record. CD4+ T-cell 
count at breast cancer diagnosis was defined as the 
closest to the date of breast cancer diagnosis. Nadir 
CD4+ T-cell count was defined as the lowest since HIV 
diagnosis up until breast cancer diagnosis. Individuals were 
considered under antiretroviral therapy if they were receiv-
ing treatment at breast cancer diagnosis.
Breast cancer among HIV+ women
Table 1. Socio-demographic and risk factor characteristics for each case reported
 Age Race Smoking Alcohol Hyper- Obesity Age at Number Reported Hormone Family 
 (years)   use tension  first of breast- use history 
       pregnancy preg- feeding (> 5 years) of BrCa 
       (years) nancies  
Case 1 50 Non-white No No Yes No 27 4 Yes Yes No
Case 2 38 Non-white No No Yes Yes 19 4 Yes No No
Case 3 46 White No No Yes No 19 8 Yes No No
Case 4 43 Non-white Yes Yes No No 28 3 No Yes Yes
Case 5 44 White No N/A No No 23 2 Yes No No
Case 6 36 White Yes N/A No No 21 4 No Yes No
Case 7 48 White Yes No Yes No 20 4 No No Yes
Case 8 54 White Yes Yes Yes No 37 1 No Yes No
Case 9 59 Non-white Yes Yes Yes No 23 3 Yes N/A No
N/A, not available; BrCa, breast cancer.
RESULTS
Nine cases of breast cancer have occurred. Median age at breast 
cancer diagnosis was 46 years (range 36-59 years). Two patients 
reported family history of breast cancer and five reported smok-
ing. All patients reported previous pregnancies, four women 
did not breastfeed. Breast cancer diagnosis was made within 2 
to 15 years of HIV-infection diagnosis. At breast cancer diagno-
sis, CD4+ T-cell counts ranged from 135 to 782 cells/mm3; six 
women were receiving HAART. Histological analysis indicated 
infiltrating ductal carcinoma in all cases. For two patients surgi-
cal treatment was not possible due to poor clinical conditions 
deriving from acquired immunodeficiency syndrome (AIDS). 
Five deaths have occurred, two due to AIDS-related condi-
tions, two due to breast cancer, and one of unknown cause. 
Median survival after breast cancer diagnosis was of 12 months 
(range: 6-46 months).
During the study period, 860 women enrolled into the 
cohort, comprising 6,745 persons/year of follow-up time, 
which yields an incidence rate of breast cancer among 
HIV-infected women of 0.00133 cases per persons/year, or 
133 cases per 100,000 persons/year.
Following, we describe the nine cases of breast cancer. 
Two tables accompany these descriptions giving the follow-
ing information: socio-demographic and general risk factor 
characteristics (Table 1), and HIV infection and breast can-
cer disease characteristics (Table 2).
Case 1
Case 1 was a 50-year old woman, non-white, menarche at 
14, first pregnancy at 27, four pregnancies, having breast-
fed. She had a history of hypertension and hormone use. 
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No family history of breast cancer was reported. HIV di- 
agnosis occurred in July 1998. Two years after HIV 
diagnosis, physical examination revealed a lump of 6.0 
cm at its larger diameter, located in the upper outer 
quadrant of her right breast, adherent to the skin, and 
papillae eversion. There was a hard lymph node, pain- 
less and mobile in the ipsilateral axilla. Histopathological 
study showed infiltrating ductal carcinoma by core biopsy. 
Staging was T4/N1/Mx; the tumor was hormone receptor 
negative. At breast cancer diagnosis, the patient was in use 
of HAART and her CD4+ T-cell count was 174 cells/mm3. 
 Chemotherapy was initiated and substituted by radia-
tion therapy due to concomitant opportunistic infec-
tion. Surgery was never performed due to lack of clini-
cal conditions. HIV disease progressed to death due to 
AIDS 12 months after cancer diagnosis, with no evidence 
of metastasis.
Case 2
Case 2 was a 38-year old woman, non-white, menarche 
at 12, first pregnancy at 19, four pregnancies, having 
breastfed. She was obese and had hypertension. No fam-
ily history of breast cancer was reported. HIV-infec-
tion was diagnosed in April 1999. Four years after HIV 
diagnosis, she developed a nodule in the upper outer 
quadrant of her left breast which, at physical examina-
tion, had 2.5 cm at its larger diameter, was hard and 
not mobile. There was no palpable axillary lymph node. 
Histopathological study showed infiltrating ductal car-
cinoma. Staging was T4/N0/M0; the tumor was hor-
mone receptor positive. At breast cancer diagnosis, she 
was receiving HAART and her CD4+ T-cell count was 
751 cells/mm3. She was submitted to mastectomy and axil-
lary dissection, with lack of involvement of the 22 lymph 
nodes resected. She received chemotherapy and tamoxifen. 
Disease progressed to liver and pulmonary metastasis with 
death occurring 46 months after breast cancer diagnosis.
Case 3
Case 3 was a 46-year old woman, white, menarche at 13, first 
pregnancy at 19, eight pregnancies, having breastfed. No 
family history of breast cancer was reported. HIV-infection 
was diagnosed in February 1996. Eight years after HIV di-
agnosis she developed a painless nodule in the upper inner 
quadrant of her right breast which, at physical examina-
tion, had 3.0 cm at its larger diameter, was hard and mobile. 
There were 1.5 cm lymph nodes, mobiles, fibroelastic, pain-
less, and bilateral in axillary area. Histopathological study 
showed infiltrating ductal carcinoma by core biopsy. Staging 
was T2/N1/M0; the tumor was hormone receptor positive. 
At breast cancer diagnosis, she was receiving dual NRTI and 
her CD4+ T-cell count was 600 cells/mm3. She was submit-
ted to mastectomy and axillary dissection, presenting in-
volvement of 9 of the 21 lymph nodes resected. She received 
chemotherapy and radiation therapy. She abandoned breast 
cancer treatment and died of an unknown cause 33 months 
after breast cancer diagnosis.
Case 4
Case 4 was a 43-year old woman, non-white, menarche at 13, 
first pregnancy at 28, three pregnancies, not having breast-
fed. She reported drinking, smoking (20 cigarettes/day), and 
hormonal use for more than five years. There was a family 
history of breast cancer (maternal aunt). HIV-infection was 
diagnosed in October 1992. Five years after HIV diagnosis 
she developed a nodule in her right breast which, at physi-
cal examination, had 3.0 cm at its larger diameter, was hard 
and mobile. In two months the tumor grew to 5.0 cm, with 
a 2.0 cm ipsilateral axillary lymph node. Fine needle aspira-
tion yielded infiltrating ductal carcinoma, confirmed by core 
biopsy. Staging was T2/N1/Mx; the tumor was hormone re-
ceptor negative. At breast cancer diagnosis, she was receiv-
ing dual NRTI, and her CD4+ T-cell count was 500 cells/mm3. 
She received chemotherapy; a scheduled subsequent surgery 
was not performed due to lack of clinical conditions. The 
patient died 12 months after the breast cancer diagnosis, 
due to opportunistic infections and chemotherapy toxicity.
Case 5
Case 5 was a 44-year old woman, white, menarche at 13, 
first pregnancy at 23, two pregnancies, having breastfed. No 
family history of breast cancer was reported. HIV-infection 
was diagnosed in February 2001. Four years after HIV di-
agnosis she developed a nodule in the lower inner quad-
rant of her right breast which, at physical examination, had 
2.0 cm at its larger diameter, was hard and mobile. There were 
no palpable lymph nodes. Core biopsy was performed yield-
ing infiltrating ductal carcinoma. Staging was T2/N1/M0; 
the tumor was hormone receptor positive. At breast cancer 
diagnosis, she was receiving HAART, and her CD4+ T-cell 
count was 782 cells/mm3. She underwent quadrantectomy 
with axillary resection one month after breast cancer diag-
nosis. One year later, radical mastectomy was performed, 
and she received chemotherapy and radiation therapy. She 
later developed brain metastasis and died 26 months after 
breast cancer diagnosis.
Case 6
Case 6 was a 36-year old woman, white, menarche at 14, 
first pregnancy at 21, four pregnancies, not having breast-
fed. She reported smoking (23 years, 20 cigarettes/day), 
hormone use, and no family history of breast cancer. 
HIV-infection was diagnosed in December 1992. Fifteen 
years later she reported a palpable nodule near the nipple of 
her right breast which, at physical examination, had 2.5 cm 
at its larger diameter, was painless and not mobile. There 
were no palpable axillary lymph nodes. Breast ultrasound 
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scan revealed two bilateral solid nodules. A core biopsy 
was performed in the right breast nodule yielding infiltrat-
ing ductal carcinoma. Staging was T3/N0/M0; the tumor 
was hormone receptor negative. At breast cancer diagnosis, 
she was receiving HAART, and her CD4+ T-cell count was 
413 cells/mm3. She received chemotherapy, was submitted 
to surgery and later treated with chemotherapy and radia-
tion therapy. Additional exams did not show metastasis. 
As of September 2009 she was alive and without evidence 
of breast cancer disease or metastasis.
Case 7
Case 7 was a 48-year old woman, white, menarche at 9, first 
pregnancy at 20, four pregnancies, not having breastfed. 
She reported smoking (25 years, 20 cigarettes/day), hy-
pertension and family history of breast cancer (mother). 
HIV-infection was diagnosed in September 1993. In 2008 
she performed a mammography that indicated category 5 
BIRADS (Breast Imaging Reporting and Data System) re-
sult, with a normal clinical exam. A puncture biopsy was 
performed in the left breast yielding infiltrating ductal carci-
noma. Staging was T1a/N0/Mx; the tumor was hormone re-
ceptor negative. At breast cancer diagnosis, she was not un-
der antiretroviral treatment, and her CD4+ T-cell count was 
287 cells/mm3. She was submitted to surgery in March 2009; 
there was no need for chemotherapy or radiation therapy. 
As of September 2009 she was alive and without evidence of 
breast cancer disease or metastasis.
Case 8
Case 8 was a 54-year old woman, white, menarche at 9, first 
pregnancy at 37, one pregnancy, not having breastfed. She 
reported hypertension, smoking (33 years, 40 cigarettes/day) 
and hormone use; no family history of breast cancer. HIV-
infection was diagnosed in March 1993. Fifteen years later, 
she performed a mammography that indicated category 5 
BIRADS result, with a normal clinical exam. A puncture 
biopsy was performed in her right breast yielding infiltrat-
ing ductal carcinoma. Staging was T1/N0/M0; the tumor 
was hormone receptor positive. At breast cancer diagnosis, 
she was receiving HAART, and her CD4+ T-cell count was 
596 cells/mm3. She was submitted to mastectomy in 
March 2009, and is currently using tamoxifen. As of Sep-
tember 2009 she was alive and without signs of breast cancer 
disease or metastasis.
Case 9
Case 9 was a 59-year old woman, non-white, menarche at 
11, first pregnancy at 23, three pregnancies, having breast-
fed. She reported smoking (35 years, 40 cigarettes/day), 
hypertension, and no family history of breast cancer. 
HIV-infection was diagnosed in June 1996. Thirteen years 
later, a breast lump of 3.0 cm, with irregular borders, hard-
ened, mobile and painless was noted in the lower outer quad-
rant of the right breast with no palpable axillary lymph nodes. 
A mammography performed indicated category 4 BIRADS. 
Core biopsy was performed yielding infiltrating ductal car-
cinoma. Staging was T2/N1/M0. At breast cancer diagnosis, 
she was receiving HAART, and her CD4+ T-cell count was 
135 cells/mm3. The treatment proposed was chemotherapy 
and subsequent surgery evaluation. As of September 2009, 
she had held two cycles of chemotherapy and the analysis 
of the tumor hormone receptor susceptibility is in progress.
DISCUSSION
The impact of HAART on the HIV epidemic includes 
greater life expectancy, a decreased risk of AIDS-defining 
cancers, and an increased risk of some non-AIDS-defin-
ing cancers.3,21,22 Breast cancer incidence has not been 
shown to be higher among HIV-infected individuals.21,22 
Among women, a pattern of decreasing risk of breast 
cancer has been shown with increasing time since AIDS 
diagnosis.23 Among men and women, a statistically signif-
icant decrease in the incidence of breast cancer has been 
observed following the AIDS epidemic in Tanzania.24 
In France, the incidence of breast cancer was significantly 
lower in HIV-infected women than in the French general 
population7,8 This apparent deficit in breast cancer cases 
may be explained by underreporting or competing mor-
tality. In the United States, the deficit of breast cancer cas-
es among women followed in the Women’s Interagency 
HIV Study is explained by an overall lower frequency of 
established risk factors.25,26
In this study, we estimated an incidence rate of breast 
cancer among HIV-infected women that is similar to 
that observed in the general female population of Brazil. 
Recently, the Brazilian National Cancer Institute estimated 
an incidence rate of breast cancer of 120 cases per 100,000 
people/year for the city of Rio de Janeiro.15 The prolonged 
survival and aging of HIV-infected patients together 
with the decreasing mortality derived from opportunistic 
infections may explain the similar incidence rates.
A more comprehensive understanding of the impact of 
HIV disease on breast cancer incidence and mortality re-
quires further studies. Breast cancer series in HIV-infected 
individuals are still limited.10-14 The largest series reported to 
date describes 20 cases among women.12 In the latter, the 
median survival time from diagnosis was of 2.2 years. In our 
series, we observed a median survival time of 12 months. 
The clinical course of breast cancer in the setting of HIV 
infection might be worse than in the non-HIV patient due 
to the inability to deliver full doses of systemic anti-cancer 
therapies. Indeed, the presence of HIV infection has been 
shown to significantly influence the toxicity of chemothera-
py.12 It is also possible that chemotherapy can adversely im-
pact on the natural history of HIV.
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Several risk factors for breast cancer have been de-
scribed; the most well-known are age over 35 years, family 
history (in particular mother or sister), pre-menopause, 
history of atypical hyperplasia or lobular carcinoma in 
situ, and documented genetic susceptibility (BRCA 1 
and 2 mutation).27,28 Factors related to intense and pro-
longed estrogen exposition, including null parity, ovulatory 
dependent sterility, early menarche, late menopause, first 
pregnancy after 34 years of age, chronic use of hormones 
for more than five years are important risk factors.27,28 Life-
style related factors are also suggested to influence breast 
cancer risk, such as obesity, smoking, no physical activity, 
and alcohol consumption.28 Most likely, for our scenario, 
the prevalence of these risk factors is not different among 
HIV-infected women and thus the incidence of breast can-
cer should also be similar. Indeed, some of these risk fac-
tors were observed among the women composing our case 
series. All were older than 35 years of age, two reported 
family history of breast cancer, five reported smoking, 
and four reported prolonged hormone use.
Although the women in this cohort were followed with 
bi-annual gynecological evaluations that included breast 
examination, the majority of patients were late diagnosed. 
Patients in our case series presented with advanced stag-
ing, and, hence, worse prognosis. This may be related to 
the delay in scheduling the appropriate procedures needed 
to confirm suspicious lesions. The end result of the late di-
agnosis is poor survival.29 Late presentation coupled with 
poor survival is a problem in many parts of the world.30 
In Brazil, breast cancer diagnosis occurs late in the dis-
ease course, and a significant part of this delay is related to 
the fragmentation and inappropriateness of the available 
health services.17 A study performed with data from 89 
hospitals specialized in cancer treatment and seven isolat-
ed services for chemotherapy and radiotherapy, covering 
altogether 43,442 breast cancer cases showed that between 
1995 and 2002, 87.7% women were late diagnosed with 
breast cancer.31 In Brazil, since 1979, breast cancer is the 
leading cause of death due to cancer among women. 
The high mortality rate for breast cancer in Brazil is mostly 
related to the delay in the diagnosis and implementation of 
adequate treatment.32 Therefore, all efforts to expedite the 
evaluation, diagnosis and staging of potential cases should 
be made so that the usual delay in breast cancer diagnosis 
does not further impair the prognosis of the patients.
Late diagnosis may also be explained by poor screen- 
ing. In fact, differential screening access and prac-
tices among HIV-infected individuals is another ex-
planation for the decreased incidence of breast cancer 
among the HIV-infected. Those with HIV, particularly 
injection drug users and the poor, are less likely to 
be regularly screened for cancers. Indeed, screening 
among HIV-infected women enrolled in the Wom-
en’s Interagency HIV Study was lower than that re-
ported in the overall United States population.33 
Hence, more subclinical disease may be detected among 
those without HIV, which would result in an apparent 
increased incidence. In Brazil, access to mammogra-
phy is still limited through the public health system. 
Our cohort of HIV-infected women are unique in that 
they have regular contact with gynecologists and may, 
therefore, have received more recommendations to seek 
breast cancer screening. In fact, the close monitoring of 
HIV-infection and treatment represents an opportunity 
to institute other recommended health interventions.33 
As with the general population, screening strategies tar-
geting early diagnosis and treatment of breast cancer 
will positively impact the survival of these patients.
The accelerated aging process of HIV-infected individu-
als should prompt the discussion of earlier mammography 
screening for these women, as they might be subject to a risk 
of developing breast cancer earlier in life when compared to 
the general population. In our case series, the median age of 
the women diagnosed with breast cancer was 46 years, while 
in the general population the incidence rate of breast cancer 
increases with age, reaching its highest levels at ages 65-70 
years.15 Focused efforts on increasing awareness of breast 
cancer and providing easy access to cancer screening are 
key strategies to curb breast cancer occurrence among the 
HIV-infected. Also, treatment must include close monitor-
ing of the viral load, chemotherapy-related toxicity, and pro-
phylactic granulocyte colony stimulating factor (G-CSF)-
support. Physicians treating women with breast cancer and 
HIV infection must be aware of the complex interactions of 
the two therapies.
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